Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABF656 in HBeAg+ Chronic Hepatitis B
NCT00964665Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2009
- Primary completion
- Nov 2010
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 2 trial of albinterferon alfa-2b in Chronic Hepatitis B (CHB), sponsored by Novartis. Started Jul 2009; status: terminated.
02
Drugs
albinterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00964665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00964665.